Brian McCartney

Brian has responsibility to proactively monitor drug pricing reform issues – including legislative, regulatory and administrative actions at the federal and state level – that could impact strategic and business outcomes for McKesson and their customers, partners and other industry stakeholders in the U.S. pharmaceutical value chain. In addition, Brian assesses financial implications for McKesson, and develops strategies and operational solutions to manage risk and drive business value, harnessing the breadth and depth of enterprise assets and capabilities. Brian has been with McKesson for a little over a year and has close to 20 years of pharmaceutical manufacturer experience in government pricing and policy at J&J, Endo Pharmaceuticals and most recently at AstraZeneca. Brian is a subject matter expert in government price reporting that gives him a deep understanding of the U.S. pharmaceutical supply chain, including 340B, buy and bill and diverse payer segments.